Compare Schlumberger NV (SLB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs TG Therapeutics Inc — how do they compare? Schlumberger NV trades at $46.6 (market cap $69.36B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: Schlumberger NV is far larger — about 8.4× TG Therapeutics Inc's market cap, and Schlumberger NV pays a 2.54% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SLB | TGTX | |
|---|---|---|
Market Cap | $69.36B | $8.26B |
Sector | Energy | Health |
52-Week High | $58.01 | $59.06 |
52-Week Low | $31.72 | $26.39 |
Enterprise Value | $77.58B | $8.50B |
Dividend Yield | 2.54% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
